Article Contents ::
- 1 The Brand Name RIDAZIN Has Generic Salt :: Thioridazine
- 2 RIDAZIN Is From Company Sun Priced :: Rs. 57.45
- 3 RIDAZIN have Thioridazine is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name RIDAZIN Has Generic Salt :: Thioridazine
RIDAZIN Is From Company Sun Priced :: Rs. 57.45
RIDAZIN have Thioridazine is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Drug Dose ::
Schizophrenia Adult: Initially, 50-100 tid daily and slowly titrated upwards at no more than 100 mg wkly. Max: 800 mg daily in 2-4 divided doses. Child: 2-12 yr: Initially, 0.5 mg/kg daily in divided doses, increased gradually until optimum effect obtained. Max: 3 mg/kg daily. DepressionAdult: Initially, 25 mg tid, titrated to 20-200 mg daily. Renal impairment: Lower initial doses and more gradual dosage increase.Hepatic impairment: Lower initial doses and more gradual dosage increase.
Hypersensitivity to phenothiazines, comatose states, pre-exisitng CNS depression, severe CVS disorders, uncorrected hypokalaemia or any electrolyte imbalance, known or suspected QT prolongation, history of ventricular arrhythmias including torsades de pointes and porphyria. Bone-marrow suppression, phaeochromocytoma, or prolactin-dependent tumours, angle-closure glaucoma, history of jaundice, parkinsonism, DM, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia, or urinary retention. Patients with reduced activity of cytochrome P450 isoenzyme CYP2D6.
Drug Precautions ::
Pregnancy, lactation; renal or hepatic impairment, epilepsy. Perform ECG screening and electrolyte measurement before therapy, after each dose increase and at 6-mthly intervals. Monitor for visual defects on long-term therapy. May impair ability to perform skilled tasks. Withdrawal of drug to be carried out gradually over 1-2 wk.
Drug Side Effects ::
Drowsiness, sedation, dry mouth, nasal congestion, blurring of vision, tremor, mydriasis, constipation, urinary retention, tachycardia, postural hypotension, sexual dysfunction, pigmentary retinopathy (high doses and prolonged therapy), contact dermatitis, tardive dyskinesias. Potentially Fatal: Neuroleptic malignant syndrome. Sudden deaths due to cardiac arrhythmias and arrest.
Pregnancy category ::
Drug Mode of Action ::
Thioridazine, a phenothiazine antipsychotic, exhibits strong beta-adrenergic blocking effects and depresses the release of hypothalamic and hypophyseal hormones by blocking postsynaptic mesolimbic, dopaminergic receptors in the brain.
Drug Interactions ::
Potentiates adverse effects of anticholinergics. Concurrent use of TCAs leads to raised blood levels of both drugs. May antagonise effects of levodopa, bromocriptine and other dopamine agonists. Avoid co-admin with drugs that cause electrolyte imbalance. Monitor phenytoin therapy due to inconsistent effects of thioridazine on phenytoin levels. Potentially Fatal: Increased risk of QT prolongation with class IA and class II antiarrhythmics, astemizole, cisapride, pimozide, droperidol, erythromycin IV, sparfloxacin, terfenadine, clarithromycin and other drugs that may prolong QT interval. Potentiates CNS depression with opioids. Increased risk of arrhythmias with ephedrine-like drugs e.g. phenylpropanolamine. Increased thioridazone levels with fluovoxamine, pindolol, propranolol, ritonavir and other CYP2D6 isoenzymes inhibitors (e.g. fluoxetine, paroxetine).